Use of Antiplatelet Inhibitors in Peripheral Vascular Interventions

ABSTRACT

In the past decade, a tremendous amount of information has been gathered about platelet function and its impact on percutaneous vascular interventions. Strategies for prevention of platelet aggregation have moved beyond aspirin administration. Powerful oral antiplatelet agents such as ticlopidine (Ticlid) and clopidogrel (Plavix) have been developed to prevent platelet aggregation and thrombosis. The discovery of the glycoprotein IIb/IIIa receptor, which is responsible for platelet aggregation, has led to the development of receptor antagonists. These drugs include abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). Several large studies have demonstrated that these drugs can improve outcomes in coronary interventions. Because most of the data regarding antiplatelet agents in percutaneous interventions comes from studies of coronary interventions, knowledge of these studies is necessary before using the antiplatelet drugs in peripheral vascular interventions. This article reviews the use of these agents in percutaneous coronary artery interventions and discusses their potential use in peripheral interventions.

Blood - platelets - arteries - transluminal angioplasty - thrombosis - drugs

REFERENCES

• 1 Weiss H. Impaired platelet-connective-tissue reaction in man after aspirin ingestion.  Lancet. 1967;  2 495-497
• 2 Dresser H. Pharmakologisches über Aspirin (acetylsalicyl Säure).  Pflugers Arch. 1899;  76 306-318
• 3 Breddin H K. Antiplatelet agents in cardiovascular and cerebrovascular diseases.  Clin Appl Thromb Hemost. 1998;  4 87-95
• 4 Awtry E, Loscalzo J. Aspirin.  Circulation. 2000;  101 1206-1218
• 5 Popma J J, Ohman E M, Weitz J, Lincoff A M, Harrington R A, Berger P. Antiplatelet therapy in patients undergoing percutaneous coronary intervention.  Chest. 2001;  119 321S-336S
• 6 Barnathan E S, Schwartz J, Taylor L et al.. Aspirin and dipyridamole in prevention of acute coronary thrombosis complicating coronary angioplasty.  Circulation. 1987;  76 125-134
• 7 Schwartz L, Bourassa M G, Lesperance J et al.. Aspirin and dipyridamole in prevention of restenosis after percutaneous transluminal coronary angioplasty.  N Engl J Med. 1988;  318 1714-1719
• 8 Antiplatelet Trialists' Collaboration . Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
• 9 Smith Jr S C, Dove J T, Jacobs A K et al.. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary.  Circulation. 2001;  103 3019-3041
• 10 Moliterno D J, Topol E J. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction.  Thromb Haemost. 1997;  78 214-219
• 11 Stavropoulos S W, Solomon J A, Soulen M C, Clark T W, Shlansky-Goldberg R D. Use of abciximab during infrainguinal peripheral vascular interventions: initial experience.  Radiology. 2003;  227 657-661
• 12 Benenati J, Shlansky-Goldberg R, Meglin A et al.. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.  J Vasc Interv Radiol. 2001;  12 795-805
• 13 Kereiakes D J. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?.  Am Heart J. 1999;  138 S39-S46
• 14 Becker R C. Thrombosis and the role of the platelet.  Am J Cardiol. 1999;  83 3E-6E
• 15 Roth G J, Calverley D C. Aspirin, platelets and thrombosis: theory and practice.  Blood. 1994;  83 885-898
• 16 Topol E J, Yadav J S. Recognition of the importance of embolization in atherosclerotic vascular disease.  Circulation. 2000;  101 570-580
• 17 Sabatine M S, Jang I K. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.  Am J Med. 2000;  109 224-237
• 18 Scarborough R M, Kleiman N S, Phillips D R. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?.  Circulation. 1999;  100 437-444
• 19 Kereiakes D J, Runyon J P, Broderick T M, Shimshak T M. IIb's are not IIb's.  Am J Cardiol. 2000;  85 23C-31C
• 20 Mascelli M A, Lance E T, Damaraju L, Wagner C L, Weisman H F, Jordan R E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.  Circulation. 1998;  97 1680-1688
• 21 The EPIC Investigators . Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation.  N Engl J Med. 1994;  330 956-961
• 22 Topol E J, Ferguson J J, Weisman H F et al.. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.  JAMA. 1997;  278 479-484
• 23 Topol E, Califf R, Wiesman H F et al.. Randomised trial of coronary interventions with antibody against IIb/IIIa integrin for reduction of clinical restenosis.  Lancet. 1994;  343 881-886
• 24 The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.  N Engl J Med. 1997;  336 1689-1696
• 25 The ERASER Investigators . Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study).  Circulation. 1999;  100 799-806
• 26 The EPISTENT Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.  Lancet. 1998;  352 87-92
• 27 The IMPACT-II Investigators . Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II.  Lancet. 1997;  349 1422-1428
• 28 Leon M B, Baim D S, Donald S et al.. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.  N Engl J Med. 1998;  339 1665-1671
• 29 The ESPRIT Investigators . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.  Lancet. 2000;  356 2037-2044
• 30 Ferguson J J. What have we learned from ESPRIT? What will we learn from TARGET?.  J Invasive Cardiol. 2000;  12 317-319
• 31 Herrmann H C. Tirofiban: an overview of the phase III trials.  J Invasive Cardiol. 1999;  11 7c-13c
• 32 A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.  N Engl J Med. 1998;  338 1498-1505
• 33 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.  N Engl J Med. 1998;  338 1488-1497
• 34 Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.  Circulation. 1997;  96 1445-1453
• 35 Topol E J, Moliterno D J, Herrmann H C et al.. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.  N Engl J Med. 2001;  344 1888-1894
• 36 Memon M A, Blankenship J C, Wood G C, Frey C M, Menapace F J. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.  Am J Med. 2000;  109 213-217
• 37 Tcheng J E. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.  Am Heart J. 2000;  139 S38-S45
• 38 Chamberlin J R, Lardi A B, McKeever L S et al.. Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro).  Catheter Cardiovasc Interv. 1999;  47 143-147 , discussion 148
• 39 Lunney L, Karim K, Little T. Vasoseal hemostasis following coronary interventions with Abciximab.  Cathet Cardiovasc Diagn. 1998;  44 405-406
• 40 Sesana M, Vaghetti M, Albiero R et al.. Effectiveness and complications of vascular access closure devices after interventional procedures.  J Invasive Cardiol. 2000;  12 395-399
• 41 Warren B S, Warren S G, Miller S D. Predictors of complications and learning curve using the Angio-Seal closure device following interventional and diagnostic catheterization.  Catheter Cardiovasc Interv. 1999;  48 162-166
• 42 Dasgupta H, Blankenship J C, Wood G C, Frey C M, Demko S L, Menapace F J. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.  Am Heart J. 2000;  140 206-211
• 43 Moliterno D J, Califf R M, Aguirre F V et al.. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.  Am J Cardiol. 1995;  75 559-562
• 44 Madan M, Kereiakes D J, Hermiller J B et al.. Efficacy of abciximab readministration in coronary intervention.  Am J Cardiol. 2000;  85 435-440
• 45 Tcheng J E, Kereiakes D J, Braden G A et al.. Readministration of abciximab: interim report of the ReoPro readministration registry.  Am Heart J. 1999;  138 S33-S38
• 46 Dyke C M. Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective.  Am Heart J. 1999;  138 307-316
• 47 Dyke C M, Bhatia D, Lorenz T J et al.. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.  Ann Thorac Surg. 2000;  70 866-871
• 48 Wallace R C, Furlan A J, Moliterno D J, Stevens G H, Masaryk T J, Perl II J. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor.  AJNR Am J Neuroradiol. 1997;  18 1257-1260
• 49 Qureshi A I, Suri M F, Khan J, Fessler R D, Guterman L R, Hopkins L N. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.  Neurosurgery. 2000;  46 1316-1324
• 50 Connors J JI, Wojak J C. Intracranial angioplasty.  J Invasive Cardiol. 1998;  10 298-303
• 51 New G, Roubin G S, Iyer S S, Vitek J J. Use of the glycoprotein IIb/IIIa inhibitor eptifibatide in a patient undergoing carotid artery stenting.  J Invasive Cardiol. 2000;  12 23D-24D
• 52 Cenena F A, Hoelzinger D H, Miller J A, Abu-Shakra S A. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions.  J Interv Cardiol. 1999;  12 355-361
• 53 Wholey M H, Wholey M H, Eles G et al.. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.  J Endovasc Ther. 2003;  10 33-41
• 54 Herbert J, Dol F, Bernat A et al.. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.  Thromb Haemost. 1998;  80 512-518
• 55 Bossavy J P, Thalamas C, Sagnard L et al.. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans.  Blood. 1998;  92 1518-1525
• 56 Moshfegh K, Redondo M, Julmy F et al.. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.  J Am Coll Cardiol. 2000;  36 699-705
• 57 Schomig A, Neumann F J, Kastrati A et al.. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.  N Engl J Med. 1996;  334 1084-1089
• 58 Moloney B A. An Analysis of the Side-Effects of Ticlopidine New York; Springer-Verlag 1993
• 59 Bennett C L, Connors J M, Carwile J M. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
• 60 Hankey G J. Clopidogrel and thrombotic thrombocytopenic purpura.  Lancet. 2000;  356 269-270
• 61 A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.  Lancet. 1996;  348 1329-1339
• 62 Bertrand M E, Rupprecht H J, Urban P, Gershlick A H, Investigators F T. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).  Circulation. 2000;  102 624-629
• 63 Berger P B. Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified.  Am Heart J. 2000;  140 354-358
• 64 Muller C, Buttner H J, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.  Circulation. 2000;  101 590-593
• 65 Mehta S R, Yusuf S. and the CURE Investigators . The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.  Eur Heart J. 2000;  21 2033-2041
• 66 Mehta S R, Yusuf S, Peter R JG et al.. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet. 2001;  358 527-533
• 67 Kleiman N S, Grazeiadei N, Maresh K et al.. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.  Am Heart J. 2000;  140 492-501